- Home
- ANIX vs PYXS Comparison
ANIX vs PYXS Comparison
Compare ANIX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- PYXS
- Stock Information
- Founded
- ANIX 1982
- PYXS 2018
- Country
- ANIX United States
- PYXS United States
- Employees
- ANIX N/A
- PYXS N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- PYXS Health Care
- Exchange
- ANIX Nasdaq
- PYXS Nasdaq
- Market Cap
- ANIX 82.7M
- PYXS 76.1M
- IPO Year
- ANIX 1987
- PYXS 2021
- Fundamental
- Price
- ANIX $3.08
- PYXS $1.28
- Analyst Decision
- ANIX Strong Buy
- PYXS Strong Buy
- Analyst Count
- ANIX 2
- PYXS 6
- Target Price
- ANIX $8.50
- PYXS $9.20
- AVG Volume (30 Days)
- ANIX 120.2K
- PYXS 551.2K
- Earning Date
- ANIX 03-11-2025
- PYXS 03-20-2025
- Dividend Yield
- ANIX N/A
- PYXS N/A
- EPS Growth
- ANIX N/A
- PYXS N/A
- EPS
- ANIX N/A
- PYXS N/A
- Revenue
- ANIX N/A
- PYXS $16,146,000.00
- Revenue This Year
- ANIX N/A
- PYXS N/A
- Revenue Next Year
- ANIX N/A
- PYXS N/A
- P/E Ratio
- ANIX N/A
- PYXS N/A
- Revenue Growth
- ANIX N/A
- PYXS N/A
- 52 Week Low
- ANIX $2.07
- PYXS $1.23
- 52 Week High
- ANIX $4.20
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- ANIX 55.10
- PYXS 32.91
- Support Level
- ANIX $2.78
- PYXS $1.23
- Resistance Level
- ANIX $3.30
- PYXS $1.40
- Average True Range (ATR)
- ANIX 0.21
- PYXS 0.09
- MACD
- ANIX -0.01
- PYXS 0.00
- Stochastic Oscillator
- ANIX 66.15
- PYXS 15.15
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.